| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.008 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.09 | 0.008 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.008 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.009 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.098 | 0.009 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.12 | 0.01 |